– SWITZERLAND, Schlieren – Virometix today announced that it has raised CHF 1.2 million from new shareholders in an extension to its recent Series A financing round. The additional funds will be used to further speed up development of its vaccine candidates for RSV and cancer immunotherapy. Furthermore, the company announced the appointment of Harry Welten, MBA as new independent member of its Board of Directors.
Mr. Welten brings in more than 20 years of international senior executive experience, 17 of which as Chief Financial Officer in biotech. He is CFO of Kuros AG (formerly Cytos) and a member of the Board of Kanyos, BiognoSYS, ProteoMediX and Horizon Pharma. Furthermore, he is a member of the foundation council of HBM Foundation. Mr. Welten will replace Prof. John Robinson, who stepped down from the Board of Directors earlier this year to now support the company as a member of the Scientific Advisory Board. With the appoint of Mr Welten, Virometix takes a further step in to enhance its professional expertise in the Board of Directors.
Mr Welten, stated “Joining Virometix’ Board of Directors is a true honor for me. I am looking very much forward to helping create value for people, shareholders and employees“.
“We are delighted to have attracted additional funding from experienced investors and cordially welcome Harry Welten to our Board of Directors, said Arin Ghasparian, CEO of Virometix “With his background in finance he will be an excellent fit for us as we progress with our development.”
Pierre Morgon, Chairman of Virometix, added “With the successful completion of our financing rounds, Virometix is on course to deliver its objectives and to advance several vaccine and cancer immunotherapy candidates. Harry will bring pivotal experience and skills in terms of financial management and deal making at an important time of the life of the company”.
About Virometix AG
Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and cancer. In an increasingly global world there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases, including cancer. Fast growing demands, health threats from newly arising complex viral and bacterial pathogens and increasingly stringent requirements for stability, safety and tolerability require new approaches to tackling current and future challenges. Rational molecular design, chemical synthesis and Virometix’ proprietary “Synthetic Virus-Like Particle” platform technology allow for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability.
For more information about Virometix AG please visit: www.virometix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
